Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

待确认 10 由做不出实验发布于 2025/2/13 23:23:42

DOI:10.1016/S2213-2600(22)00437-4
作者：Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem,&nb
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in patien

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

6小时前

biofresh

5bad5b32ea2011efb35f34735aa3bc31.pdf

6小时前

Book学术机器人

2025/2/13 23:23:42 未找到该文献，机器人已退出，请等待人工下载

2025/2/13 23:23:42 Book学术AI机器人收到请求，开始寻找文献

2025/2/13 23:23:42 已向机器人发送请求

6小时前

做不出实验发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库The gut-brain axis in multiple sclerosis: Focus on the role of the gut microbiota in neuroinflammation